Objective: Previous studies have demonstrated the importance of somatic mutations and arginine residues in the complementarity determining regions (CDRs) of pathogenic anti-dsDNA antibodies in human and murine lupus. Studies of murine antibodies suggested that mutations at position 53 in V H CDR2 are important.
Systemic lupus erythematosus (SLE) is characterised by the presence of autoantibodies directed against a wide variety of different antigens. Antibodies to double-stranded DNA (anti-dsDNA) are especially important (1) . Serum levels of these antibodies frequently reflect disease activity (2) and their presence correlates with the occurrence of renal disease (3, 4) . In both clinical studies and animal models, pathogenicity is associated with IgG isotype and with high affinity binding to dsDNA rather than ssDNA (1, 2) . However, only some anti-dsDNA antibodies are pathogenic in mice and this pathogenicity does not always correlate with affinity for dsDNA (5) (6) (7) (8) . This finding implies that dsDNA is not the only clinically relevant antigen in the pathogenesis of lupus nephritis. In particular, nucleosomes and alpha-actinin have been suggested as pathologically relevant antigens by different groups (9) (10) (11) (12) .
Sequence analysis of murine and human monoclonal anti-dsDNA antibodies (13, 14) has shown multiple somatic mutations in their heavy chain variable region (V H ) and light chain variable region (V L ) sequences. These somatic mutations are not distributed randomly but are clustered in the complementarity determining regions (CDRs), which form the antigen-binding site, suggesting that they are antigen-driven.
Antigen-driven somatic mutation in many of these high affinity monoclonal antidsDNA antibodies results in accumulation of arginine (R), asparagine (N) and lysine (K) in the CDRs. (13, 15, 16) In-vitro expression experiments have shown that altering R residues in the CDRs of these antibodies can lead to significant alterations in binding to dsDNA (17) (18) (19) (20) (21) but few studies have looked at the influence of particular somatic mutations on binding to nucleosomes or alpha-actinin.
It is increasingly accepted that the generation and affinity maturation of autoantibodies in SLE is driven by the presence of autoantigens present on cell fragments released by apoptosis. Clearance of these fragments is retarded in patients with SLE (22) . These autoantigens include nucleosomes, anionic phospholipids (PL) and beta-2-glycoprotein I (β 2 GPI). Anti-PL and anti-β 2 GPI antibodies are important in the pathogenesis of the antiphospholipid syndrome (APS), which often co-exists with SLE. Within β 2 GPI, binding to epitopes on the N-terminal domain -Domain Iis particularly important in APS (23) .
It is important to distinguish the somatic mutations in CDRs that enhance binding to multiple antigens on apoptotic cell debris from the mutations that focus binding onto a particular antigen involved in pathogenesis (e.g nucleosomes). In murine and human antibodies some arginine residues have been shown to enhance binding to both dsDNA and PL (21, 24) and others enhance binding to one of these antigens but have no effect on the other (25) .
Amino acids at certain positions within CDRs seem likely to play a critical role in determining the binding properties of autoantibodies. Position 53 in V H CDR2 is an important site of antibody-antigen contact in a number of murine anti-DNA antibodies (13) particularly the murine antibody 3H9 where R53 is important in binding to ssDNA, dsDNA, PL and β 2 GPI (24) . An arginine at position 53 of V H CDR2 of the human monoclonal IgG1 antibody B3 appears to make a critical interaction with dsDNA in a computer model of the B3-DNA complex (26) . B3 binds more strongly to nucleosomes than to dsDNA (27) and also binds cardiolipin (PL) (25) . There is evidence that B3 is pathogenic in severe combined immunodeficiency (SCID) mice (5, 27) . In previous experiments we showed that the prediction of the computer model that R27a in B3V L was important in binding dsDNA/nucleosomes was confirmed by a reduction in binding when R27a was altered to serine (S) (20) . In the current experiment we used similar techniques to investigate the importance of V H R53 on binding to a range of antigens, to test the hypothesis that the introduction of this R played a critical role in making B3 a high-affinity anti-nucleosome antibody. B3V H is derived from germline gene V H 3-23, but differs from it at a number of sites other than R53. To test the effect of R53 in isolation we expressed germline V H 3-23 with and without introduction of R at position 53.
Materials and Methods
Human monoclonal antibodies from which the expressed V H and V L sequences were derived B3 (28), 33H11 (16) and UK4 (29) are all human IgG monoclonal antibodies produced from lymphocytes of three different patients. 33H11 was a kind gift from Dr. Thomas Winkler (Erlangen, Germany). B3 and UK4 were produced in the laboratories of the authors in London. The V L regions of all three antibodies are encoded by the gene 2a2 and therefore show >90% homology. They differ only at sites of somatic mutation as shown in Figure 1 . The chimeric light chains B33 and BU were constructed such B33V L is exactly the same as B3V L up to a Kpn I site in FR2 and exactly the same as 33H11V L after it. BUV L is exactly the same as B3V L up to the Kpn I site and exactly the same as UK4V L after it.
Assembly of constructs for expression
The wild type heavy and light chain constructs, the chimeric light chain constructs and the point mutant B3(R27aS)V L were prepared as detailed fully in previous papers (30, 31) .
A plasmid (neSLE122H45.4) that encodes a human V H 3-23, D6-25, J H 5 IgH chain was a kind gift from Dr Hedda Wardemann (The Rockefeller University, New York, USA). This VDJ sequence was amplified by PCR to incorporate a HindIII restriction site at the 5' end and a XhoI site at the 3' end of the J region. The insert was then ligated into a final expression vector that contains Cγ1 constant region cDNA.
Site-directed mutagenesis of B3V H
The aim of mutagenesis was to produce variant forms of B3V H in which the positively charged R residue at position 53 had been altered to S which is uncharged and which is present at that position in the unmutated sequence of V H 3-23 (germline reversion), N which is also uncharged, or K which is positively charged. We also made a variant of the germline V H 3-23 sequence in which S53 was mutagenized to R. The Quikchange site-directed mutagenesis kit (Stratagene,UK) was used to create all mutations. The primers used are shown in Table 1 .
Transient expression of whole IgG molecules
The whole IgG molecules were expressed in COS-7 cells as described previously (30) . Equal quantities (10µg) of recombinant heavy chain and recombinant light chain vector were transfected into 10 7 COS-7 cells in 700µl phosphate buffered saline (PBS) by electroporation (1.9 kV, 25µF). In each transfection experiment, a negative Due to the relatively low concentrations of IgG produced by the transient expression system, the cell supernatants were concentrated prior to the ELISA analysis using Centricon-YM30 centrifugal concentrators (Millipore,UK).
Stable expression of whole IgG molecules
Eight different IgG secreting lines were made. The lines were designated 1) SVBL
The method used for the production of the stable cell lines is described in (27) . A negative control CHO line was prepared by electroporation of the CHOdhfr -cells in the absence of plasmid DNA.
Affinity purification of antibody from CHO cells
The cell lines were transferred to Chemicon Europe Ltd Southampton, UK and expanded in larger quantities. Human IgG was purified from the supernatant using a Protein A column and the product was analysed for purity by SDS PAGE and quantified by spectrophotometry. Purified human IgG was sent back to our unit where the amount of whole IgG antibody was quantified by ELISA.
Detection and quantification of whole IgG molecules by ELISA
Whole IgG molecules were detected and quantified using a direct ELISA, as described in previous papers (20, 25, 30) .
Detection of binding to DNA and nucleosomes by ELISA
The dsDNA was prepared and used in an anti-DNA ELISA, as described previously (31) . Binding to ssDNA was tested using exactly the same protocol except that the dsDNA was denatured by boiling at 100 o C for 30 minutes before being used to coat the plates. Nucleosomes were prepared and used in an anti-nucleosome ELISA as described previously (27) .
Detection of binding to alpha-actinin by ELISA
Binding of IgG molecules to alpha-actinin was measured by direct ELISA using the method described previously (32) .
Detection of binding to cardiolipin by ELISA
The binding of IgG molecules to CL in the presence of fetal calf serum (FCS), containing β 2 GPI, was measured by direct ELISA as described previously (25) . In some cases, the CL ELISA was modified by replacing the FCS with human serum to test whether the presence of human β 2 GPI was important.
Detection of binding to β β β β 2 GPI by ELISA
The binding of IgG molecules to human β 2 GPI was measured by direct ELISA as described previously (25) . The human β 2 GPI ELISA was modified by replacing the human β 2 GPI with bovine β 2 GPI (SCIPAC, UK) for the purpose of testing speciesspecificity of the binding of purified IgG antibodies.
Detection of binding to purified recombinant hexahistidine(his 6 )-tagged Domain I of β β β β 2 GPI by ELISA Recombinant his 6 -tagged Domain I was produced by expression in Escherichia coli, as described elsewhere (33) . The direct binding ELISA to purified recombinant his 6 -tagged DI was performed as described previously (33) .
Detection of binding to ovalbumin by ELISA
Monoclonal antibodies were also analysed by ELISA for binding to ovalbumin as previously described (34) using maxisorp (Nunc, UK) microtitre plates. We went on to test the combinations of V H 3-23 and V H 3-23(S53R) with all four light chains in assays of binding to CL, alpha-actinin, β 2 GPI and Domain I. There was no binding to any of these antigens (data not shown).
Results

Transient expression in COS-
Stable expression of whole IgG molecules in CHO cells
Four stably transfected lines -SVBL (secreting the combination B3V H /B3V L ), SVB33
(secreting B3V H /B33V L ), SVBLX (secreting B3V H /B3(R27aS)V L ) and SVBU (secreting B3V H /BUV L ) had previously been produced and submitted to methotrexate amplification (27) . We produced four more lines SVBL(R53S), SVBL(R53N), SVBL(R53K) and SVB33(R53S) in this study. These lines secrete The R53S mutation enhances binding to whole β β β β 2 GPI and Domain I of β β β β 2 GPI Figure 3c shows binding of the eight affinity-purified antibodies to β 2 GPI. Binding was only seen at concentrations 10 times higher than those that gave binding of the wild-type B3V H /B3V L to nucleosomes. As with alpha-actinin, however, the introduction of the R53S mutation enhances binding to β 2 GPI. B3(R53S)V H /B3V L binds β 2 GPI whereas B3V H /B3V L does not. Similarly, B3(R53S)V H /B33V L binds
Interestingly, on this occasion the R27aS mutation in B3V L also enhances binding because B3V H /B3(R27aS)V L binds β 2 GPI whereas B3V H /B3V L does not. The loss of this light chain R has not previously been found to enhance binding to any antigen (20, 31) . We chose to study binding to nucleosomes and alpha-actinin because of the evidence that antibodies that react with these antigens are important in pathogenesis of lupus nephritis. Two groups have shown that binding to alpha-actinin is an important factor determining the pathogenicity of anti-dsDNA antibodies in mouse models (9, 10, 35) .
These results were supported in a clinical study (32) . No group has previously published an analysis of effects of somatic mutations in human anti-dsDNA antibodies on ability to bind alpha-actinin. Sequence analysis of pathogenic murine anti-alpha-actinin antibodies did not suggest that any particular sequence features favour binding to alpha-actinin (9).
Anti-nucleosome antibodies are found in patients with SLE (36) and develop before anti-dsDNA antibodies in murine models of lupus (37) . Some antibodies known to be pathogenic in mice were initially thought to bind naked dsDNA but have subsequently been shown to bind nucleosomes or chromatin instead (11, 27, 38) .
Anti-nucleosome antibodies are thought to cause glomerulonephritis by formation of nucleosome/anti-nucleosome complexes, which interact with heparan sulphate in the glomerular basement membrane (11, 12). Wellmann et al (19) recently showed that two somatic mutations in the light chain and one in the heavy chain of the human monoclonal anti-dsDNA antibody 33.C9 were essential for binding to either dsDNA or nucleosomes.
Cocca et al (24) showed that reversion of an R at position 53 in the heavy chain of the murine anti-dsDNA antibody 3H9 to serine reduces binding to DNA, PL, β 2 GPI and apoptotic cells. They suggested that some autoantibodies are produced in response to autoantigens derived from apoptotic cell debris and that some somatic mutations could therefore enhance binding to several such antigens. Accumulation of further mutations might then be expected to increase the affinity of the antibody for one autoantigen while reducing its affinity for others. Our experiments showed that B3V H /B3V L binds nucleosomes at much lower antibody concentrations than the concentrations of B3(R53S)V H /B3V L required to bind alpha-actinin and β 2 GPI. The computer model of the B3/dsDNA complex showing an interaction between dsDNA and R53 suggests a mechanism by which R53 could be important in affinity maturation of this antinucleosome antibody (26) . An alternative hypothesis is that the R53 residue does not contact dsDNA directly, but stabilizes a protein structure that supports the antibody combining site. Since the germline sequence of V H 3-23 did not confer intrinsic binding to any of the antigens tested, our results could suggest that a precursor of B3 accumulated some somatic mutations to attain relatively broad but low affinity antigen-reactivity including alpha-actinin and β 2 GPI, but that the introduction of the heavy chain S53R somatic mutation created an antibody with specificity and high affinity for nucleosomes. It should be noted however, that unmutated V H 3-23 in combination with other D and J sequences than the one we tested is known to encode a number of polyreactive antibodies (reviewed in 14 and 24).
Several authors have noted a preponderance of R, N and K residues at the antigenbinding sites of human and murine anti-dsDNA antibodies (13, 14, 16) . Using a database of 1875 antibody sequences Collis et al (39) showed that both R and N, but binding to dsDNA and nucleosomes than R53S but we did not find this to be the case.
It seems likely that a property of R apart from charge or hydrogen bond formation is crucial to its interaction with dsDNA in B3. Perhaps the length and shape of the arginine side chain are important. In contrast R53S, R53N and R53K had very different effects on interaction with alpha-actinin and Domain I of whole β 2 GPI. Only the germline reversion R53S enhanced binding to those antigens. Heavy/light combinations containing R53N and R53K did not bind any antigen except ovalbumin.
In our previous paper (34) we found that alteration of arginines in IS4V H CDR3 to serines led to an increase in binding to ovalbumin and hypothesized that this might be due to a reversal of serine to arginine somatic mutations that took place during affinity maturation. However, we could not be sure of this since the germline sequence corresponding to IS4V H CDR3 is unknown. In the current paper, however, the germline reversion R53S did not increase binding to ovalbumin even though it increased binding to other antigens. We conclude that the identity of the residue at position 53 is very important in determining antigen-specificity of the antibodies that we tested, but the effects of particular changes in this residue are difficult to predict.
The production of an antibody, B3(R53S)V H /B3V L which was found to bind human but not bovine β 2 GPI was unexpected and has not previously been described. Zhu et al (40) reported two human IgG monoclonal antibodies IS1 and IS2 that bound bovine but not human β 2 GPI. Sequence analysis later showed that these antibodies were derived from the same B cell clone (41) . There are 11 amino acid differences between the sequence of Domain I of human and bovine β 2 GPI, therefore it is likely one of these differences plays a role in the specificity of B3(R53S)V H /B3V L for human β 2 GPI. Our group has expressed two variant forms of Domain I of human β 2 GPI that specifically target these residues of interest, therefore it will be possible in future experiments to determine the binding affinity of B3(R53S)V H /B3V L to these variant forms.
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